ESPR Esperion Therapeutics Inc.

-0.52  -1%
Previous Close 51.57
Open 51.31
Price To Book 7.85
Market Cap 1374136129
Shares 26,917,456
Volume 224,164
Short Ratio
Av. Daily Volume 678,843

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date February 26, 2020.
Bempedoic Acid/ Ezetimibe
PDUFA date February 21, 2020.
Bempedoic acid
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data due 2H 2019.
Bempedoic Acid/ Ezetimibe (1002-058)
LDL-C and type 2 diabetes
Phase 3 enrolment to be completed 3Q 2019.
Bempedoic Acid (ETC-1002) CLEAR Outcomes
Cardiovascular Diseases

Latest News

  1. Esperion to Participate in Upcoming Investor Conferences
  2. Esperion Gets a Go-Ahead from the FDA
  3. Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates
  4. Esperion Therapeutics: 1Q Earnings Snapshot
  5. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
  6. Esperion to Host Analyst and Investor Day Event on May 30
  7. A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why
  8. Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today
  9. Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications
  10. Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
  11. Here’s What Hedge Funds Think About Esperion Therapeutics, Inc. (ESPR)
  12. Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors
  13. Weekly CEO Buys Highlight
  14. Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
  15. Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $200,000 of Shares
  16. Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
  17. Esperion Therapeutics (ESPR) Down 12.9% Since Last Earnings Report: Can It Rebound?
  18. Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions